Skip to main content

HealthTimes

Stakeholders at a Zimbabwe social contracting and HIV financing dialogue in Harare
Health News HIV/AIDS

Zimbabwe Looks to Strengthen Social Contracting as HIV Donor Funding Shrinks

Michael Gwarisa

By Michael Gwarisa Despite meeting the UNAIDS 95-95-95 targets overall, Zimbabwe’s HIV response could face growing pressure if it fails to secure alternative funding to cover gaps left by international donors and development partners, delegates to the Transition Initiative Stakeholder Dialogue on Health financing  have warned. The warning comes as Zimbabwe seeks to strengthen an

Read More
Chief Nyamaropa during a traditional court proceeding in Shamva where a woman was ordered to pay a beast over alleged HIV transmission
HIV/AIDS

HIV decriminalisation tested as traditional court orders woman to pay cow over alleged transmission

Michael Gwarisa

By Michael Gwarisa Zimbabwe abolished a law that criminalised HIV transmission four years ago. But a recent traditional court case in Shamva has raised fresh questions about whether people living with or affected by HIV can still face punitive consequences outside the formal criminal justice system. Chief Nyamaropa, Munyaradzi Tivange, recently ordered a woman to

Read More
Protesters at AIDS 2026 raise concerns about HIV among Indigenous people
Global Health HIV/AIDS

Fiji’s HIV Epidemic Has Moved Beyond Its Initial Risk Group

Michael Gwarisa

By Michael Gwarisa Fiji has moved from describing HIV as an outbreak initially concentrated among people who inject drugs to declaring a national HIV emergency, as new data show the epidemic spreading beyond the population at the centre of the country’s initial response. The change marks a significant development in an HIV epidemic that has

Read More
Dolutegravir pill used in HIV treatment
HIV/AIDS medical research Pedriactic Health

FDA Approves Drug to Treat HIV Infection in Newborns

Michael Gwarisa

By Michael Gwarisa The U.S. Food and Drug Administration (FDA) has approved a new formulation of the HIV medicine dolutegravir for use in newborns from birth through four weeks of age, expanding treatment options for one of the most vulnerable groups at risk of HIV infection. The approval covers Tivicay PD tablets for oral suspension

Read More
Women holding their babies queue at a Zimbabwean health facility as new AIDS 2026 data warn that PEPFAR disruptions have reduced HIV treatment support for thousands of children.
Breaking News Global Health HealthTimes Premium HIV/AIDS

Zimbabwe Among Hardest Hit as New PEPFAR Data Shows Over 6,000 Children Lose HIV Treatment Support

Michael Gwarisa

By Michael Gwarisa Zimbabwe is among the countries hardest hit by recent disruptions to the United States President’s Emergency Plan for AIDS Relief (PEPFAR), with new data released ahead of the International AIDS Society (IAS) Conference on HIV Science (AIDS 2026) showing that more than 6,000 fewer children were receiving PEPFAR-supported HIV treatment by the

Read More
Kenneth Ngure, President-elect of the International AIDS Society, discusses landmark Phase III trial results for a once-weekly HIV pill ahead of AIDS 2026.
Global Health HealthTimes Premium HIV/AIDS Reseach Findings

Once-Weekly HIV Pill Matches Daily Treatment in Landmark Phase III Trials Ahead of AIDS 2026

Michael Gwarisa

By Michael Gwarisa A once-weekly pill for HIV treatment has performed as well as standard daily therapy in two landmark Phase III clinical trials, bringing researchers a step closer to offering people living with HIV the world’s first complete once-weekly oral treatment regimen. The findings from the ISLEND-1 and ISLEND-2 studies will be presented at

Read More
A woman prepares to take a daily oral PrEP pill, illustrating HIV prevention and adherence before the rollout of long-acting injectable Lenacapavir in Zimbabwe.
Breaking News Health News HIV/AIDS

Daily Pill Burden Fuels Demand for Long-Acting HIV Prevention in Zimbabwe, Survey Finds

Michael Gwarisa

By Michael Gwarisa Nearly seven in ten Zimbabweans who previously used daily oral HIV prevention pills abandoned treatment because of the burden of taking medication every day, a new survey has revealed, adding fresh evidence that long-acting injectable HIV prevention could transform the country’s fight against new HIV infections. The findings come just months after

Read More
Malawi health officials receive the country's first shipment of lenacapavir HIV prevention doses during the official handover ceremony.
Africa HIV/AIDS

38,000 Malawians to Receive Lenacapavir as First Shipment of HIV Prevention Doses Arrives

Michael Gwarisa

By Michael Gwarisa Malawi has received its first shipment of lenacapavir, a long-acting injectable HIV prevention medicine, with enough doses expected to protect 38,000 people, marking another milestone in Africa’s rollout of one of the most significant advances in HIV prevention in decades. The arrival of the first of two planned shipments positions Malawi as

Read More
Breaking News HIV/AIDS

Zimbabwe Study Finds Older People Living with HIV Face Hidden Bone Loss, Women at Greatest Risk

Michael Gwarisa

By Michael Gwarisa A groundbreaking Zimbabwean study has revealed that older people living with HIV have significantly poorer bone health than their HIV-negative peers, with women facing an even greater risk of developing osteoporosis and suffering debilitating fractures as they age. Published in the Journal of Bone and Mineral Research, the study found that HIV

Read More
Moses Moyo, inmate educator at Khami Maximum Prison in Zimbabwe, teaching fellow prisoners inside a classroom
Features HIV/AIDS

Inside Khami Prison: The Inmate Called “The Headmaster” Transforming Education Behind Bars

Kuda Pembere

By Kuda Pembere As he walks into the classroom, the room falls silent. A silence that settles whenever a figure of authority steps into the space. Rows of inmates sit shoulder to shoulder, carefully writing letters and numbers into neatly covered exercise books. The room is bright, orderly and filled with focus. One young inmate

Read More